Search

Displaying results 1241 - 1250 of 4600 in total
  1. Drug

    Renzapride

    go.drugbank.com/drugs/DB04917
    Investigational

    It is being developed by Alizyme of the UK.

  2. Drug

    Ethylmorphine

    go.drugbank.com/drugs/DB01466
    IllicitInvestigational

    It is metabolized in the liver by ethylmorphine-N-demethylase and used as an indicator of liver function. It is not marketed in the US but is approved for use in various countries around the world. … In the US it is a schedule II drug (single-entity) and schedule III drug (in combination products).

  3. Drug

    Pramocaine

    go.drugbank.com/drugs/DB09345
    Approved

    Pramocaine is available by itself and in combination with other medications in various topical preparations. … It works by preventing ionic fluctuations needed for neuron membrane depolarization and action potential propagation.

    Mixtures: Up and Up Hemorrhoidal, Up and Up multi action antibiotic
  4. Drug

    Insulin glulisine

    go.drugbank.com/drugs/DB01309
    Approved

    combined with once daily, long-acting "basal insulin" such as [DB01307], [DB09564], and [DB00047] to provide low concentrations of background insulin that can keep blood sugar stable between meals or overnight … If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening

    Products: APIDRA 100 U/ML- SOLUTION FOR INJECTION IN VIAL, APIDRA 100 U/ML SOLOSTAR ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 5 ADET
  5. Drug

    Eflornithine

    go.drugbank.com/drugs/DB06243
    ApprovedInvestigationalWithdrawn

    [A262823,L49318] Subsequently, on December 14, 2023, the FDA approved eflornithine again but under the brand name IWILFIN as an oral maintenance therapy to reduce the risk of relapse in adult and pediatric … [A262839] In 1960 and 2000, the FDA approved eflornithine under the brand names ORNIDYL and VANIQUA for the treatment of African trypanosomiasis and hirsutism, respectively, but has since been discontinued

  6. Drug

    Ixekizumab

    go.drugbank.com/drugs/DB11569
    ApprovedInvestigational

    Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing.

  7. Drug

    Donanemab

    go.drugbank.com/drugs/DB16647
    ApprovedInvestigational

    [A232214] On July 2, 2024, donanemab was approved by the FDA for the treatment of AD in patients with mild cognitive impairment or dementia symptoms.

  8. Drug

    MC-1

    go.drugbank.com/drugs/DB05315
    Experimental

    Medicure's MC-1 drug is a cardio-protectant, designed to reduce the damage to the heart when arteries are blocked and when they are subsequently reopened after bypass surgery.

  9. Drug

    Trimethobenzamide

    go.drugbank.com/drugs/DB00662
    ApprovedInvestigational

    Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). … In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against emesis induced by intragastric copper sulfate.

  10. Drug

    Labetalol

    go.drugbank.com/drugs/DB00598
    ApprovedInvestigational

    Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture.